Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282984 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT00282984 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 714 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00282984, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Varenicline
Study Locations (20)
Other
- Pfizer Investigational Site - Brno
- Pfizer Investigational Site - Prague
- Pfizer Investigational Site - Aarhus C
- Pfizer Investigational Site - Hellerup
- Pfizer Investigational Site - Caen
- Pfizer Investigational Site - Marseille
- Pfizer Investigational Site - Toulouse
Buenos Aires
- Pfizer Investigational Site - Capital Federal
- Pfizer Investigational Site - Ciudad de Buenos Aires
Ontario
- Pfizer Investigational Site - London
- Pfizer Investigational Site - Ottawa
Quebec
- Pfizer Investigational Site - Drummondville
- Pfizer Investigational Site - Québec
Connecticut
- Pfizer Investigational Site - Hartford
Massachusetts
- Pfizer Investigational Site - Boston
Wisconsin
- Pfizer Investigational Site - Madison
New South Wales
- Pfizer Investigational Site - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282984
The ClinicalTrials.gov registry entry for NCT00282984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (52% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00282984 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Buenos Aires, Ontario.
Frequently Asked Questions
What is clinical trial NCT00282984 about?
NCT00282984 is a clinical study titled "Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking". The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
What is the current status of trial NCT00282984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 714 participants. The study started on 2006-02. Estimated completion is 2008-08.
What conditions does trial NCT00282984 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00282984?
The interventions under investigation include: placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT00282984?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00282984 being conducted?
This trial has 20 study locations across Connecticut, Massachusetts, Wisconsin, Buenos Aires, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.